Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 28, 2026Scientific ReportsOpen Access

Impact of ABCB1 polymorphisms on response to anthracycline chemotherapy in breast cancer patients

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAli AbuhaliemaAYAl-Motassem YousefNENirmeen Elmadany

Discussion

Loading...

Member takes

Overview

Cohort study demonstrates improved disease-free survival with the ABCB1 C3435T CC genotype in older breast cancer patients, suggesting genetic variation influences anthracycline response.

Key Points

  • To evaluate whether common single nucleotide polymorphisms in the ABCB1 gene alter clinical response and survival outcomes in breast cancer patients receiving doxorubicin-based chemotherapy.
  • Conducted an exploratory cohort study of 122 breast cancer patients from a Middle-Eastern population treated with doxorubicin-based chemotherapy.
  • Genotyped participants for three ABCB1 single nucleotide polymorphisms (C3435T, G2677A/T, and C1236T) and evaluated outcomes using Cox regression and haplotype analyses.
  • Patients aged 50 years and older carrying the C3435T CC genotype showed significantly improved disease-free survival compared to those with CT and TT genotypes.
  • The G2677A/T polymorphism showed a non-significant trend toward an increased risk of disease progression in Cox regression analysis.
  • The C1236T variant and haplotype analyses showed no clear association with patient treatment outcomes.

Cite This Study

Abuhaliema et al. (2026) studied this question.

synapsesocial.com/papers/6a91468ad15324a1df3aa481https://doi.org/10.1038/s41598-026-67792-4
View Full Paper
Ask AI
Bookmark
Share